President/CEO of Conceptus Inc. (CPTS, Financial) Mark M Sieczkarek sells 95,387 shares of CPTS on 09/23/2009 at an average price of $19 a share.
Conceptus Inc. designs and develops minimally invasive devices for reproductive medical applications. Conceptus' focus is to develop its STOP non-surgical permanent contraception device for women. STOP is designed to be a less-invasive safer and less costly alternative to surgical sterilization more commonly known as tubal ligation. The STOP device is designed to achieve contraception by elliciting a tissue response which occludes the fallopian tubes. Conceptus Inc. has a market cap of $570.1 million; its shares were traded at around $18.65 with a P/E ratio of 169.5 and P/S ratio of 5.6.
CPTS is in the portfolios of PRIMECAP Management.
Recent Trades of Conceptus Inc. by CEO:
Recent Trades of Conceptus Inc. by Directors and Officers:
CPTS is in the portfolios of PRIMECAP Management.
Recent Trades of Conceptus Inc. by CEO:
- Sell: President/CEO Mark M Sieczkarek sold 4,613 shares of CPTS stock on 09/09/2009 at the average price of $19; the price of the stock has decreased by 1.84% since.
Recent Trades of Conceptus Inc. by Directors and Officers:
- Sell: VP of Sales Ulric E Iii Cote sold 9,013 shares of CPTS stock on 09/09/2009 at the average price of $19; the price of the stock has decreased by 1.84% since.
- Sell: VP of Sales Ulric E Iii Cote sold 987 more shares of CPTS stock on 08/25/2009 at the average price of $19; the price of the stock has decreased by 1.84% since.
- Sell: VP of Sales Ulric E Iii Cote sold 5,000 more shares of CPTS stock on 08/07/2009 at the average price of $18; the price of the stock has increased by 3.61% since.
- Sell: Chairman of the Board Kathryn Tunstall sold 30,000 shares of CPTS stock on 06/12/2009 at the average price of $16.31; the price of the stock has increased by 14.35% since.
